Effect of Ertugliflozin on Cardiac Function in Diabetes

  • End date
    Jun 30, 2022
  • participants needed
  • sponsor
    Soo Lim
Updated on 5 April 2021


The aim of this study is to investigate the beneficial role of ertugliflozin, a new SGLT2 inhibitor, in cardiac function via measuring GLS as well as other hemodynamic factors using echocardiogram in patients with T2D and HF, who are not controlled with oral antidiabetic medications including DPP4 inhibitors.


This study is a phase 3, randomized, double-blind, active-competitor, parallel-group study that is anticipated to enroll 120 patients. Patients taking metformin and/or DPP4 inhibitors as per local label for 12 weeks without a dose adjustment before enrollment will be eligible for screening. All patients will have a screening period comprised of an up to 2-week screening phase prior to randomization. In order to qualify for randomization, patients must demonstrate compliance based upon pill count (80%) and discretion of the investigators during the Run-in phase.

Glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) will be masked to patients after randomization. To prevent partial unblinding, urinary glucose excretion (UGE) results will be masked to patients. Urine glucose, albumin, calcium, and creatinine will be measured separately on-site visits.

Condition Heart failure, Heart disease, Type2 Diabetes, Congestive Heart Failure, Cardiac Disease, cardiac failure, congestive heart disease
Treatment Placebo, Ertugliflozin
Clinical Study IdentifierNCT03717194
SponsorSoo Lim
Last Modified on5 April 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 20 yrs and 75 yrs?
Gender: Male or Female
Do you have any of these conditions: Heart failure or Type2 Diabetes or cardiac failure or Congestive Heart Failure or congestive heart disease or Cardiac Disease or Heart disease?
Do you have any of these conditions: Congestive Heart Failure or Cardiac Disease or Heart failure or congestive heart disease or cardiac failure or Type2 Diabetes or Heart disease?
Do you have any of these conditions: Type2 Diabetes or cardiac failure or Congestive Heart Failure or Heart failure or Heart disease or congestive heart disease or Cardiac Disease?
Patients with T2D taking oral antidiabetic medications (metformin and/or DPP4 inhibitors) except SGLT2 inhibitors for at least 12 weeks without a dose adjustment before enrollment
eGFR 45 mL/min/1.73 m2
Stage B HF identified on the basis of either structural or functional markers

Exclusion Criteria

Type 1 diabetes mellitus
At the time of screening age <20 years
HbA1c <7% or HbA1c >9.5% at Screening
FPG >15 mmol/L (270 mg/dL) measured by the laboratory at Screening (Visit 1), and confirmed (>15 mmol/L [>270 mg/dL]) by a repeat test before randomization
Treated with insulin and/or GLP-1R agonist within 12 weeks preceding the Screening Visit
Women of childbearing potential with no effective contraceptive method
History of gastric surgery including history of gastric banding within 3 years before the Screening Visit
History of diabetic ketoacidosis or nonketotic hyperosmolar coma prior to the Screening Visit
Mean blood pressure after 3 separate measurements >180 mmHg in systolic blood pressure (SBP) or >95 mmHg in diastolic blood pressure (DBP)
Patients with current or prior symptoms of HF
Patients with severe anemia, severe respiratory, hepatic, neurological, psychiatric disorders or active malignant tumor or other major systemic disease or patients with short life expectancy making implementation of the protocol or interpretation of the study results difficult
Aspartate aminotransferase and/or alanine aminotransferase: >3 times the upper limit of the normal laboratory range (ULN)
Total bilirubin: >1.5 times ULN (except in case of Gilbert's syndrome)
Use of systemic glucocorticoids (excluding topical or ophthalmic, application or inhaled forms) for more than 10 consecutive days within 90 days prior to the Screening Visit
Patient who has taken other investigational drugs or prohibited therapy for this study within 3 months
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note